118 results about "Drug release rate" patented technology

The invention provides a sleep-aiding medicine pillow dynamic regulation and control method and system based on physiological parameter analysis. According to the method, pressure data and sleep bio-electricity signals of a contact area of a user are collected in real time, a characteristic frequency band proportion and a heart rate fluctuation parameter are analyzed, and a correlation model is established; calculating a bioelectricity signal energy integral value of the characteristic frequency band based on the model, and quantizing to generate a bioelectricity intensity index; the heat conduction efficiency is changed by adjusting the molecular density of the temperature-sensitive material, and a contact layer heat transfer dynamic instruction is generated; pressure feedback and instruction waveform characteristics are combined, the micropore on-off duty cycle is adjusted, and the opening duration of unit time is controlled; the drug release rate is synchronously adjusted, so that the response waveform and the heat conduction instruction are dynamically balanced, and closed-loop regulation is formed. According to the application, through multi-parameter dynamic analysis and feedback adjustment, accurate cooperative control of heat conduction and medicine release of the medicine pillow is realized, and the matching degree of sleep-aiding substance release and sleep rhythm is optimized.

The invention relates to a composite hydroxypropyl methylcellulose skeleton sustained-release material and a preparation method thereof, and belongs to the technical field of drug sustained release. The sustained-release material is prepared from 70 to 90 parts of hydroxypropyl methylcellulose (HPMC), 10 to 20 parts of sodium alginate, 8 to 15 parts of chitosan, 0.1 to 0.2 part of Omega-3 fatty acid, 0.05 to 0.06 part of vitamin D, 2.5 to 5 parts of soluble calcium salt-zinc salt composite cross-linking agent, 0.5 to 1.5 parts of hydrolyzable cross-linking agent, 3 to 10 parts of enzyme sensitive auxiliary material, 1 to 5 parts of pore-foaming agent and 2 to 8 parts of hydrophobic blocking agent. The preparation method comprises the steps of raw material pretreatment and dry mixing, active component dispersion liquid preparation, wet granulation and primary cross-linking, secondary cross-linking and drying, vacuum drying and size stabilization, curing and packaging and the like. The sustained-release material provided by the invention has the advantages of controllable drug release rate, good mechanical strength and biodegradability, is suitable for sustained-release delivery of Omega-3 fatty acid, vitamin D and other active components, and can improve the bioavailability and stability of drugs.

The invention provides a thermo-sensitive block polymer as well as a preparation method and application thereof. The temperature-sensitive block polymer comprises a temperature-sensitive unit, a hydrophilic unit and a pH response unit, the number-average molecular weight of the thermo-sensitive block polymer is 1 * 10 < 3 > g / mol to 2.5 * 10 < 5 > g / mol, preferably 8 * 10 < 3 > g / mol to 2.0 * 10 < 4 > g / mol; molecular weight distribution lt; 1.50, preferably < 1.30. The preparation method comprises the following steps: mixing an RAFT reagent, an initiator, a hydrophilic polymer or a hydrophilic monomer, a temperature-sensitive monomer, a pH response monomer and a solvent, carrying out an active free radical polymerization reaction in a protective gas atmosphere, and carrying out post-treatment on a product to obtain the temperature-sensitive block polymer. The obtained thermo-sensitive block polymer is narrow in molecular weight distribution, the drug release rate is more controllable, and the drug effect is improved.

The invention relates to the technical field of drug release control. By providing a multi-modal data fusion nano-drug release kinetics prediction method, device and equipment and a medium, the method comprises the following steps: acquiring permeation path image data of a nano-drug in a target tissue, and acquiring drug release rate chemical data; performing time dimension synchronization processing on the permeation path image data and the drug release rate chemical data to generate a multi-modal space-time correlation data set; performing feature extraction processing on the multi-modal time-space correlation data set to obtain nano-drug permeation behavior features and release dynamics fluctuation features; constructing a space-time diagram neural network prediction model; training the space-time diagram neural network prediction model to obtain a trained prediction model; and generating a personalized drug release scheme through a reverse optimization algorithm on the basis of the drug release kinetics prediction curve and the quantitative index of the degree of variability, so as to achieve the technical effects of improving the prediction precision, enhancing the model adaptability and reducing the curative effect volatility.

The invention discloses a sustained-release pill as well as a preparation method and application thereof, and belongs to the technical field of medicines. The sustained-release pill comprises a pill core and a coating layer coated outside the pill core, the pellet core is prepared from the following raw materials in parts by mass: 8 to 14 parts of loxoprofen sodium, 30 to 60 parts of a filling agent, 3 to 10 parts of an adhesive, 2 to 10 parts of a disintegrating agent, 0.1 to 2 parts of a penetration enhancer, 0.05 to 0.2 part of a pH regulator, 0.1 to 0.5 part of a surfactant and 0 to 20 parts of an auxiliary agent; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin; the coating layer is prepared from an aqueous dispersion liquid containing acrylic resin. Aiming at the drug characteristics of loxoprofen sodium, the loxoprofen sodium sustained-release tablet is composed of specific auxiliary materials, the drug composition is optimized, the drug release rate is accurately controlled, the bioavailability and stability of the drug are effectively improved, and the loxoprofen sodium sustained-release tablet has a good application prospect in preparation of antipyretic and analgesic drugs.

The invention discloses a hydrogel microsphere system for sequential delivery of drugs as well as a preparation method and application thereof, and particularly relates to the technical field of biomedical materials. The microsphere system comprises inflammation responsive hydrogel microspheres obtained by grafting molecules containing inflammation responsive groups with hyaluronic acid as a skeleton, common microspheres obtained by grafting non-responsive molecules with hyaluronic acid as a skeleton, an anti-inflammatory drug and a healing promoting drug. Wherein the molecular weight of the hyaluronic acid is 74-800kDa, the inflammation responsive hydrogel microspheres are loaded with anti-inflammatory drugs, and the common microspheres are loaded with healing promoting drugs. According to the hydrogel microsphere system, the drug release rate and degradation time of the microspheres are adjusted by limiting the molecular weight of hyaluronic acid, and a molecular basis is provided for subsequent differentiated drug release.

The invention relates to the technical field of alimentary canal diagnosis and treatment, in particular to an alimentary canal detection drug delivery system which comprises an alimentary canal sensing unit for collecting an image, a pH value, a temperature and pathological tissue pathological characteristic data in an alimentary canal cavity; the lesion positioning analysis unit identifies a lesion area through an image segmentation algorithm, constructs a lesion three-dimensional coordinate model according to physiological parameters, prejudges a lesion displacement trend in combination with an alimentary canal peristalsis rule, analyzes a lesion state in stages, and outputs lesion severity; the response type drug delivery module controls the micro drug delivery device to perform targeted release and adjust the drug release rate based on the lesion coordinates and the intracavity environment parameters; the data collaboration platform shares a detection result and a drug administration record through a real-time interaction interface; the curative effect feedback unit is used for collecting physiological index change and patient symptom improvement data after drug administration, judging the drug onset period and possible adverse reactions, and optimizing drug administration parameters and detection frequency. Therefore, the problems of low targeting precision, poor diagnosis and treatment efficiency and the like in the prior art are solved.

The invention belongs to the technical field of medical treatment, and particularly relates to an analgesic anti-inflammatory drainage tube which comprises an outer tube, an inner tube and a medicine guide tube, the inner tube is arranged in the outer tube, connected with a first one-way valve and connected with the medicine guide tube through the first one-way valve, and the medicine guide tube is connected with a medicine slow release device; the medicine slow-release device comprises a slow-release cavity, a suction pump, a partition plate and a pressing mechanism, a medicine guiding cavity is fixed in the slow-release cavity and connected with a medicine guiding pipe, the partition plate is fixedly installed on the inner wall of the slow-release cavity, a through hole is formed in the middle of the partition plate, an injection pipe is connected to the right side of the bottom of the slow-release cavity, and a second one-way valve is arranged in the injection pipe. The device solves the problems that when a current drainage tube releases a medicament, the medicament release speed and the single release amount cannot be accurately adjusted, so that the medicament supply is too much or insufficient, and manual control and automatic control cannot be freely selected, so that the surgical risk is increased.

The application discloses a mouse wearable micro-injection device for slow release of rhodiolin, and relates to the technical field of medical miniaturized devices. The device comprises a fixing frame, a slow injection device arranged at the upper end of the fixing frame, and a flow guide device connected with the slow injection device. The slow injection device comprises a syringe body internally provided with a liquid storage area and a reaction area. An injection plug is arranged between the liquid storage area and the reaction area. The side edge of the injection plug is in close contact with the inner wall of the syringe body. The flow guide device is in communication with the liquid storage area. The device can realize accurate control of the drug release rate through three different reaction mechanisms, i.e. gas driving of a drug bin, physical expansion of an expansion bag and composite expansion of an expansion bin. In addition, the design of the hanging ear port in the fixing frame can not only disperse the pressure on the ears, but also reduce the fluctuation range of the mouse's corticosterone level in combination with the lightweight structure design.

The invention discloses a kinesio bandage with a slow release function and a preparation process thereof, the kinesio bandage comprises a functional spraying agent, and a contact layer, a slow release layer and a substrate layer which are laminated and compounded in sequence, and the invention relates to the technical field of kinesio. According to the kinesio bandage with the slow release function and the preparation process thereof, a functional spraying agent is independently designed, when the kinesio bandage is used, coupling of the functional spraying agent and a buffer layer is achieved by spraying the functional spraying agent to a contact layer, and under the moisture absorption effect of sodium polyacrylate moisture absorption particles, rapid gelation of the functional spraying agent on the surface of the contact layer is achieved; according to the present invention, the skin surface temperature is responded through the poloxamer 407, such that the rapid formation of the gel state of the contact layer is ensured, the drug release speed is accelerated along with the increase of the skin surface temperature, and the dynamic drug sustained release support condition is provided for the sports personnel;

The invention relates to the technical field of medicines, in particular to a budesonide-loaded oral colon targeting delivery system, a preparation method and application. According to the delivery system, budesonide entrapped by Pickering emulsion serves as a core, and a low-ester pectin-calcium ion cross-linked inner layer and a low-ester pectin-chitosan polyelectrolyte composite outer layer are sequentially wrapped on the outer layer; the preparation process is realized by combining an emulsion template method with a layer-by-layer self-assembly technology, the obtained microcapsule is of a uniform spherical structure, the particle size is about 400 microns, and the microcapsule has a double-layer three-dimensional network structure. The delivery system is kept stable in the gastrointestinal environment and releases drugs rapidly only under the colon pH condition, in-vitro simulation experiments show that the drug release rate in the stomach / small intestine stage is lower than 5%, and the drugs are released rapidly in the colon stage. Animal experiments prove that the effect of treating ulcerative colitis is equivalent to that of mesalazine, the toxicity of the whole body is remarkably reduced, the residence time of the medicine at the colon part exceeds 24 hours, and the medicine is not accumulated in a non-target organ.

The present invention relates to a coating material for drug-coated balloons, drug-coated balloons, and a coating solution for drug-coated balloons, as well as their preparation and application. The coating solution comprises an aqueous solvent and a plurality of core-shell structures dispersed in the aqueous solvent, each of which comprises a lipid bilayer coated with a drug. The core of the core-shell structure contains a plurality of drug-loaded particles, and the shell of the core-shell structure is a lipid bilayer with an outer hydrophilic group and an inner hydrophobic group. The drug-loaded particles comprise a plurality of drug-loaded nanocrystalline particles. The combination of nanocrystals and liposomes combines the advantages of these two types of drug carriers. The resulting lipid bilayer improves the solubility of poorly soluble drugs in drug-coated balloons, resulting in a high drug loading capacity, high drug carrier stability, and stable drug crystal form, allowing for controllable drug release rates.

The invention discloses a preparation method and application of a hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid conjugate nanoparticle drug delivery system, and relates to the technical field of biological pharmacy. The key points of the technical scheme are as follows: GA and FA are respectively connected with HA by using adipic acid dihydrazide as a connexon; and the hyaluronic acid-glycyrrhetinic acid and hyaluronic acid-ferulic acid polymer prodrugs are synthesized. An in-vitro release result shows that when the NPs are exposed in a physiological medium with slightly acidic pH, the drug release rate is higher than that in a blood environment with pH of 7.4. And the drug release rate and the drug release amount of the nanoparticles are superior to those of single drug release. The HA-ADH-GA and the HA-ADH-FANPs both have relatively low toxicity in vitro and a good effect of resisting the influenza A virus H1N1. Compared with the HA-ADH-FANPs, the HA-ADH-GANPs has the advantage that the HA-ADH-GANPs has a better protection effect on a mouse infected with the H1N1-UI182 in vivo.

The present invention relates to a multiple controlled-release tablet composition of ruxolitinib or a pharmaceutically acceptable salt thereof, which is useful for treating Janus kinase-associated diseases such as myeloproliferative disorders, and a method for producing the same. More specifically, the present invention relates to a multiple controlled-release tablet composition and a method for producing the same, which exhibits a maximum drug blood concentration similar to that of commercially available immediate-release formulations, while controlling the drug release rate so as to efficiently maintain the drug at or above the effective blood concentration in the body, thereby enabling once-daily administration, unlike commercially available formulations that are administered twice daily.

The present invention relates to a prodrug and drug having a controllable drug release rate. Specifically provided are a prodrug or a stereoisomer, deuterated substance, solvate, polymorph or pharmaceutically acceptable salt thereof. The prodrug contains a drug and a linker, wherein the drug is linked to the linker, and the linker contains a structure as represented by formula (1). The prodrug has a long half-life, does not require an enzymatic or redox environment, can controllably and spontaneously release the drug under physiological conditions, and exhibits a high drug delivery efficiency. The released drug exhibits a complete activity and is not affected by the linker or a macromolecular carrier.

The invention discloses an internal jugular vein semi-permanent catheter with a self-adaptive epidermal growth factor release mechanism, and belongs to the technical field of medical instruments. The catheter comprises a catheter body and a multifunctional medicine release covering film arranged at the telecentric end in a covering mode, the covering film is made of biocompatible polymers, epidermal growth factors (EGF) and antibacterial agents are loaded on the covering film in a gradient mode, and a micro sensor is arranged in the covering film. The sensor is linked with an intelligent feedback system, the drug release rate can be dynamically adjusted according to local physiological conditions, and meanwhile wireless data transmission and remote monitoring are supported. The defects of an existing semi-permanent catheter in the aspects of infection prevention, healing promotion and dynamic adjustment are overcome, targeted drug release, continuous antibiosis, self-adaptive feedback and remote management are achieved, and the long-term implantation requirement is met.

The invention relates to the technical field of drug release adjustment, and particularly discloses a drug release adjustment method and system based on sweat pH value and temperature, and the method comprises the steps: S1, obtaining sweat pH value and skin surface temperature information of a region, and obtaining a signal A and a signal B respectively; s2, preprocessing to obtain a stabilized signal; s3, calculating an instantaneous drug release rate, and quantifying to obtain a current nano preparation release efficiency coefficient; S4, driving a microneedle channel to open and control to obtain a blood concentration; s5, sampling and detecting the released blood concentration to obtain a feedback concentration signal; s6, updating the release efficiency coefficient to obtain a nano preparation release efficiency coefficient of a new period; dual signals of sweat pH and skin surface temperature are synchronously collected, stable input is generated after pretreatment, subtle changes of body surface and in-vivo physiological states can be reflected in real time, and therefore richer and more reliable basis is provided for drug release decision, and drug delivery precision is effectively improved.

The invention provides a drug carrier based on N-acetylglucosamine, a drug preparation and a preparation method. The drug carrier based on N-acetylglucosamine comprises N-acetylglucosamine and a cross-linking agent, the cross-linking agent is a compound with an aldehyde group or a ketone group, and the aldehyde group or the ketone group reacts with the deacetylated N-acetylglucosamine to generate one or more of a hydrazide bond, a hydrazone bond or an imine bond. The drug carrier based on N-acetylglucosamine shows remarkable advantages in the aspects of particle size distribution, drug loading capacity, encapsulation efficiency and cumulative drug release rate.

The application discloses a polymer vesicle-stabilized drug-iodized oil emulsion and a preparation method and application thereof, to realize safe and efficient transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma in situ. The drug-iodized oil emulsion system has the following advantages: simple preparation, convenient size adjustment, excellent stability, near-zero order and sustained controllable drug release rate, low blood drug concentration after transarterial embolization, and the retention time and retention amount of the drug in the liver are superior to those of free drug-iodized oil emulsion used in clinical treatment, the tumor can be completely eradicated, angiogenesis can be effectively inhibited, and adverse reactions can be reduced. In general, the polymer vesicle-stabilized drug-iodized oil emulsion has the advantages of high stability and sustained controllable drug release, and can greatly improve the embolization chemotherapy effect of hepatocellular carcinoma, and provide a safe and efficient TACE strategy.

The invention discloses a celecoxib capsule and a preparation method thereof, and relates to the technical field of sustained-release capsules. Sorbitol is added into medicine particles to serve as a filling agent, the particles can easily form a porous network structure after being dried, and the surface porosity is increased; the porous particles can improve the release rate of the medicine. However, the sorbitol is high in hygroscopicity and can cause caking of the medicine particles, and the nano silicon dioxide absorbs moisture, so that direct contact between the sorbitol and the environment is reduced, and the particles are prevented from being bonded and clustered after moisture absorption. Therefore, the nano silicon dioxide is added to improve the stability and reduce the moisture absorption rate. In order to accelerate dissolution, polyvinyl alcohol is used for accelerating dissolution, and meanwhile, the polyvinyl alcohol can reduce the moisture absorption rate; the polyvinyl alcohol is subjected to amination treatment, and the aminated polyvinyl alcohol can improve the hydrophilicity of the capsule, so that the transmittance of the medicine is improved, and the release rate of the medicine is improved.

This invention relates to the field of biomedical technology, specifically disclosing an anti-inflammatory and bone-promoting rhodioloside composite hydrogel and its preparation method. The thermosensitive carrier is a triple-response system, which enhances the drug release rate only in a specific microenvironment at 37°C, with a pH of 5.5-6.5 at the site of inflammation, and in which MMPs are overexpressed. MMPs are highly expressed at the implant periodontitis site, and MMP-sensitive peptides can be specifically degraded by this enzyme. This process can trigger the precise release of rhodioloside and quercetin active ingredients in the gel, avoiding systemic drug diffusion that could lead to drug waste or side effects at other sites. Rhodioloside and quercetin synergistically downregulate the expression levels of inflammatory factors such as IL-6 and TNF-α, while nisin and chitosan-ε-polylysine grafts inhibit the growth of Porphyromonas gingivalis. Runx2 / CON expression is increased, achieving a closed-loop treatment of anti-inflammatory, antibacterial, and bone-promoting effects.

The invention provides a nicotine sustained-release capsule, the nicotine sustained-release capsule comprises a content, the content comprises a sustained-release pellet, the sustained-release pellet comprises an active core, a first coating layer and a second coating layer which are sequentially arranged from inside to outside, the active core comprises at least one of nicotine or a nicotine derivative, the first coating layer comprises a first adhesive, and the second coating layer comprises a second adhesive. The second coating layer comprises a second adhesive, and the second coating layer is an enteric coating; through the design of the nicotine sustained-release capsule dosage form, the drug release rate can be delayed, the stable blood concentration can be maintained, the drug effect duration can be prolonged, the smoking process of'low-dose sustained release 'can be simulated, and the emotion and physiological reaction in the smoking cessation process can be improved; in addition, the design of the double-layer coating is also helpful for stabilizing the fluctuation of the blood concentration, and a safer, more continuous and milder nicotine release process is realized.

The present application discloses an NPs hydrogel containing semaglutide and a preparation method thereof, relating to the technical field of polymer composite materials, including the main drug, polylactic acid nanoparticles, dodecyl-modified hydroxypropyl methylcellulose, and PBS; wherein the polylactic acid nanoparticles are prepared by wrapping graphene with polyethylene glycol-polylactic acid, the main drug is semaglutide, the concentration of semaglutide in the hydrogel is 2-20 mg / ml, and the weight percentage of the polylactic acid nanoparticles and dodecyl-modified hydroxypropyl methylcellulose is 1-2 wt% of dodecyl-modified hydroxypropyl methylcellulose and 10 wt% of polylactic acid nanoparticles; it can achieve a long-term sustained and controlled release effect; and the degradation rates of the nanoparticles wrapped with graphene oxide and the nanoparticles not wrapped with graphene oxide are inconsistent, enabling further control of the drug release rate.

The invention belongs to the field of lubricating oil filter elements, and particularly relates to a cell capsule wrapped type double-treatment lubricating oil multi-agent filter element structure which comprises a filter element body. The mixing mechanism is mounted in the filter element main body and is used for sufficiently and uniformly combining the released medicament with the lubricating oil; the retaining mechanism is mounted in the filter element main body and is used for actively crushing medicament aggregates contained after the lubricating oil and the medicament are mixed; the release mechanism is mounted in the filter element main body and is used for releasing the medicament in the cell capsule in a matched manner according to the amount of the lubricating oil; the release mechanism comprises an annular cell capsule wrapping ring fixedly connected to the interior of the filter element main body, and the bottom of the annular cell capsule wrapping ring is rotationally connected with a valve disc through a bearing; a worm wheel is used for sensing flow through the release mechanism, a valve disc is driven through a gear set, accurate matching of the medicament release rate and the lubricating oil flow is achieved, and the problems that a traditional structure is not accurate in release and large in concentration fluctuation are fundamentally solved.

The application discloses a targeted magnetic nano-composite of palygorskite, a preparation method and application thereof in preparation of an in-vitro drug controlled release medicine. In the application, an anti-tumor drug DOX is loaded through an acid-cleavable acylhydrazone bond, and the drug release rate is lower in a normal physiological environment and higher in a tumor acid environment compared with electrostatic adsorption and pore storage of the DOX with HPal, so that the drug controlled release performance is obviously improved. In addition, loading of magnetic Fe3O4 nanoparticles and grafting of FA enrich the means of transporting the DOX to a designated area by the carrier, that is, the tumor cells can be positioned by external magnetic field control or receptor-ligand interaction targeting. MTT analysis and cell uptake research prove the targeting effect of the FA, and the therapeutic effect of the DOX can be effectively improved.

The invention relates to the technical field of biological medicines, in particular to a sustained-release pharmaceutical composition for treating cardiomyopathy and a preparation device thereof. An existing preparation is fast in metabolism and difficult to act for a long time in myocardial tissue. Every 10 ml of the pharmaceutical composition comprises 1 g of levocarnitine as a raw material medicine, 48 mg of sodium benzoate, 34 mg of DL-malic acid and 5 mg of saccharin sodium as auxiliary materials, hydrochloric acid used for adjusting the PH value to 4.3-4.7, and purified water added to 10 ml. Through an auxiliary material system in the composition, especially DL-malic acid, the release rate of the medicine can be adjusted, and a physical and chemical basis is provided for realizing a slow release effect, so that the medicine can be released more gently in vivo, and the effective blood concentration of the medicine can be maintained for a longer time, thereby achieving the purpose of continuously supplying energy to myocardial cells, and further achieving the aim of continuously supplying energy to the myocardial cells. The defects that the half-life period is short and the drug effect is not continuous in the prior art are overcome.

This invention relates to a choleretic traditional Chinese medicine composition, its preparation method, and its application, belonging to the field of traditional Chinese medicine preparation technology. The microcapsules prepared from this choleretic traditional Chinese medicine composition consist of a core and a coating. The core contains a traditional Chinese medicine extract, pregelatinized starch, sodium alginate, and croscarmellose sodium. The coating contains hydroxypropyl cellulose and hydroxypropyl methylcellulose E5, PEG4000, and talc. The traditional Chinese medicine extract is made from Artemisia capillaris, Lysimachia christinae, Rheum palmatum, Scutellaria baicalensis, Taraxacum mongolicum, Forsythia suspensa, Curcuma longa, Curcuma longa, Bupleurum chinense, Citrus aurantium, and Aucklandia lappa. This choleretic traditional Chinese medicine composition has the effects of promoting bile flow and expelling gallstones, detoxifying and reducing swelling, with a stable drug release rate, definite efficacy, and few toxic side effects. It can be used for the prevention and / or treatment of acute and chronic gallstones and / or cholecystitis.

The invention belongs to the technical field of hydrogel, and particularly relates to acylhydrazone bond system hydrogel and a preparation method and application thereof.The system is composed of two kinds of modified gel, one kind of modified gel is amino-containing modified sodium hyaluronate (NorHA-ADH), the other kind of modified gel is aldehyde-containing oxidized sodium alginate (OSA), and after the two kinds of components are mixed, the hydrogel is prepared into a hydrogel solution through a sol-gel method. A controllable double-crosslinking network can be formed through crosslinking of an acylhydrazone bond, and the drug carrier has various technical advantages which are mainly reflected in (1) a specific drug carrying mechanism: molecular binding selectivity is remarkably improved through directional covalent binding of an aldehyde group component and a drug amino group; (2) gradient release regulation and control: utilizing the controllable hydrolysis characteristic of an acylhydrazone bond in an acid environment to realize dynamic matching between the drug release rate and the pH value of a focus microenvironment; and (3) structure programmability: by adjusting the ratio of functional groups of the precursor, the mechanical strength and degradation kinetics of the hydrogel can be systematically adjusted to adapt to the requirements of different treatment scenes, and the controlled release effect of the system on amino drugs and the treatment effect on related diseases are obviously superior to those of a traditional sodium alginate system.

The application discloses a traditional Chinese medicine plaster for lumbar disc herniation and a preparation method thereof, and relates to the technical field of biological medicine. In the microneedle layer, macromolecular antler active components are loaded, and a liposome transition depot layer and an enzyme-responsive hydrogel controlled-release layer are constructed on the surface of the microneedle layer. Through the system integration of the three-layer structure, a complete treatment chain of puncture, transdermal penetration, transition depot, intelligent response and controlled release is constructed. The microneedle layer breaks through the physical barrier of the stratum corneum, directly delivers the antler active components and analgesic anti-inflammatory components to the dermis layer, and realizes rapid effect. The liposome transition depot layer provides secondary release and protection, maintains the drug concentration platform, and realizes continuous supply. The enzyme-responsive hydrogel controlled-release layer intelligently adjusts the drug release rate according to the pathological state of the lesion, and realizes on-demand drug release. The antler active components promote the repair of nucleus pulposus cells and nerve regeneration, and the CeO2@PDA nanoenzyme removes ROS to improve the microenvironment, realizing the treatment of both the symptoms and the root cause.

The present application relates to the technical field of medicine, and in particular to a budesonide-loaded oral colon-targeted delivery system, a preparation method and application. The delivery system takes Pickering emulsion-encapsulated budesonide as the core, and is sequentially coated with a low-ester pectin-calcium ion crosslinked inner layer and a low-ester pectin-chitosan polyelectrolyte complex outer layer. The preparation process is realized by combining an emulsion template method with layer-by-layer self-assembly technology. The obtained microcapsules have a uniform spherical structure, a particle size of about 400 μm, and a double-layer three-dimensional network structure. The delivery system remains stable in the gastrointestinal environment, and only releases drugs rapidly under colon pH conditions. In vitro simulation experiments show that the drug release rate is less than 5% in the stomach / small intestine stage, and is rapidly released in the colon stage. Animal experiments confirm that the effect of treating ulcerative colitis is equivalent to that of mesalamine, while the systemic toxicity is significantly reduced, the drug retention time at the colon site is more than 24 hours, and there is no accumulation in non-target organs.